METHODS FOR DETERMINING CHEMOSENSITIVITY AND CHEMOTOXICITY
First Claim
Patent Images
1. A method for determining an adverse response to one or more cancer treatments in a patient, comprising:
- determining a BH3 profile for the patient'"'"'s cell specimen; and
classifying the patient for likelihood of an adverse response to one or more cancer treatments.
1 Assignment
0 Petitions
Accused Products
Abstract
The present disclosure relates to diagnostic methods that are relevant to various cancers and which comprise BH3 profiling diagnostics for, among others, predication of an adverse patient response to a cancer treatment.
-
Citations
57 Claims
-
1. A method for determining an adverse response to one or more cancer treatments in a patient, comprising:
-
determining a BH3 profile for the patient'"'"'s cell specimen; and classifying the patient for likelihood of an adverse response to one or more cancer treatments. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 55, 56, 57)
-
-
50. A method for determining a treatment response to one or more cancer treatments in a blood cancer patient, comprising:
-
determining a BH3 profile for the patient'"'"'s tumor or cancer cell specimen; and classifying the patient for likelihood of one or more of an adverse response to one or more cancer treatments and a therapeutic efficacy to one or more cancer treatments wherein the a BH3 profile comprising BAD and/or PUMA responses is indicative of an adverse response to one or more cancer treatments and a BH3 profile comprising BIM and/or HRK responses is indicative of therapeutic efficacy to one or more cancer treatments. - View Dependent Claims (51, 52, 53)
-
-
54. A method for determining an adverse response to one or more cancer treatments in a patient, comprising:
-
determining a BH3 profile for the patient'"'"'s cell population that is affected by the adverse event, and classifying the patient for likelihood of an adverse response to one or more cancer treatments.
-
Specification